GPS News  
EPIDEMICS
Australia denies meddling in PNG rollout of Chinese jab
by AFP Staff Writers
Manila (AFP) July 9, 2021

Australia rejected Friday China's accusations of meddling in the rollout of Chinese-made Covid-19 vaccines in Papua New Guinea, saying it accepted countries' decisions over their choice of jab.

Relations between Canberra and Beijing have deteriorated sharply in recent years, with disputes over everything from telecoms giant Huawei to the origins of the coronavirus.

The latest spat was sparked by Chinese state media, with the Global Times tabloid accusing "Australian consultants" planted in Papua New Guinea of "obstructing" the emergency use authorisation of Chinese vaccines.

Australia's Minister for International Development and the Pacific Zed Seselja rejected the accusations on Friday.

"It's simply not true," Seselja told AFP during a visit to the Philippines.

"We accept countries' sovereign decisions about their vaccines."

China's foreign ministry spokesman Wang Wenbin had on Monday expressed concern over what he called "irresponsible behaviour" in Papua New Guinea.

He urged Australia to "stop disrupting and undermining vaccine cooperation between China and Pacific island countries".

Papua New Guinea has started rolling out 200,000 doses of China's Sinopharm vaccine that arrived in the country last month.

The Global Times article published July 2 accused Australia of "threatening" senior Papua New Guinean officials with the loss of investment in road projects if they went to the airport to welcome the arrival of the jabs.

"With Australia working in the shadows, Papua New Guinea's epidemic prevention centre did not approve the emergency use of Chinese vaccines until the end of May, when Australia-provided vaccines had already arrived in the country," it said.

Seselja said Australia was providing "comprehensive support" to its neighbour Papua New Guinea, which included the delivery so far of 28,000 doses of the AstraZeneca vaccine.

While Papua New Guinea was also getting doses "from other sources", including the Covax programme, Seselja said Australia was ready to provide enough shots to inoculate its "entire adult population".

Papua New Guinea began a nationwide vaccine rollout in May as it sought to contain an outbreak that has taken the country's caseload to more than 17,000 infections, including 177 deaths.

Vaccine misinformation is widespread and there is concern about the safety of the AstraZeneca product after a small number of widely reported health scares overseas.

Australia has pledged to share 15 million doses of Covid-19 vaccines with Pacific nations by mid-2022.

"Obviously our first priority is to make sure Australians have access to doses, but given we have got that capacity, given we've got other sources of vaccines in Australia, there will be that capacity to continue to up our effort when it comes to sharing vaccines in the region," Seselja said.

bur-amj/mff/axn

ASTRAZENECA


Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola


Thanks for being here;
We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain.

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor
$5 Billed Once


credit card or paypal
SpaceDaily Monthly Supporter
$5 Billed Monthly


paypal only


EPIDEMICS
Moderna begins human trial for multi-strain mRNA flu vaccine
Washington (AFP) July 7, 2021
US biotech firm Moderna said Wednesday it had dosed its first participants in a human study of an mRNA vaccine that targets multiple strains of influenza. The company intends to recruit 180 adults in the United States for the Phase 1/2 portion of the trial to evaluate the safety and strength of immune response to the shot, called mRNA-1010. It is based on the same messenger ribonucleic (mRNA) technology deployed in Moderna's Covid-19 shot, which is more than 90 percent effective, and if the tria ... read more

Comment using your Disqus, Facebook, Google or Twitter login.



Share this article via these popular social media networks
del.icio.usdel.icio.us DiggDigg RedditReddit GoogleGoogle

EPIDEMICS
Colorado ranchers face not just drought but rising social pressures

Colorado ranchers face not just drought but rising social pressures

Spanish govt in rib-eye rumble as minister attacks meat industry

Scientists remotely control plant's pores with light

EPIDEMICS
Concepts for the development of German quantum computers

Ultrathin semiconductors electrically connected to superconductors for the first time

UK PM reveals govt will review Chinese purchase of semiconductor firm

Broadcom settles US antitrust case on chip market

EPIDEMICS
Testing maintenance and ground processes for future aircraft generations

Turkish F-16s, troops join NATO air policing mission

Death toll in Philippines military plane crash rises to 50

Israel strikes Gaza after incendiary balloon launch

EPIDEMICS
Paris to extend 30 kph speed limit to most streets

EU slaps VW, BMW with 875-mn-euro antitrust fine

EU prepares to send petrol cars to the scrap heap

Opel to be 100% electric in Europe by 2028: CEO

EPIDEMICS
China inflation eases on the back of falling meat prices

Asian markets fall on virus fears

Samsung Electronics says Q2 operating profit to jump more than half

China deepens crypto crackdown with central bank warning

EPIDEMICS
The battle for Brazil's indigenous land hots up

New June record for deforestation of Brazilian Amazon

Colombian deforestation up 8% in 2020: ministry

Fears for future of Mexico City's 'green lung'

EPIDEMICS
Pathfinder satellite paves way for constellation of tropical-storm observers

China launches new meteorological satellite

NASA rocket, satellite tag-team to view the giant electric current in the sky

New approach could change how we track extreme air pollution events

EPIDEMICS
Custom-made MIT tool probes materials at the nanoscale

Nano-Bio Materials Consortium introduces new AFRL-Industry Co-Development Program

Nanostructured device stops light in its tracks









The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us.